Every material Form 8-K Annovis Bio, Inc. has filed with the SEC since October 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Annovis Bio agreed on November 5, 2026 to sell 19,000,000 shares of common stock (or pre-funded warrants in lieu of shares) with accompanying warrants, with expected gross proceeds of approximately $21.0 million before underwriting discounts and expenses. The offering adds shares and warrants that could dilute existing shareholders, while the company plans to use the proceeds for clinical development of buntanetap and working capital.
Offering of 19,000,000 shares plus pre-funded warrants for up to 2,000,000 shares, with accompanying warrants for up to 21,000,000 shares, priced at $1.00 per share and accompanying warrant
Accompanying warrants are exercisable at $1.00 per share and expire five years after issuance
One of the company's directors is buying 5,000,000 shares and accompanying warrants for $5,000,000
Offering is expected to close on or about November 6, 2026, with Canaccord Genuity LLC as underwriter
Annovis Bio said in a preliminary, unaudited estimate that it had approximately $2.8 million in cash and cash equivalents as of September 30, 2026. The company has not finished its quarterly closing process, and its auditor has not reviewed the figure, so the final results may differ.
Estimated cash and cash equivalents: approximately $2.8 million as of September 30, 2026
Interim financial statements for the three and nine months ended September 30, 2026 are not yet available
Independent registered public accounting firm has not reviewed or expressed an opinion on the estimates
Annovis Bio received a New York Stock Exchange notice on October 29, 2026, that it no longer meets continued listing standards because its 30-day average market capitalization and stockholders' equity were both below $50 million. The company has 9 months to regain compliance, and its common stock will keep trading under the symbol ANVS with a ".BC" designation while it works on a plan.
NYSE notice received October 29, 2026, under Section 802.01B of its Listed Company Manual
30-day average market capitalization was approximately $48.4 million as of October 28, 2026
Stockholders' deficit was approximately $(4.3) million as of June 30, 2026
Company must submit a compliance plan within 45 days of the notice; cure period is 9 months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Annovis Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →